giant larvae by the atypical protein kinase C and partitioning-defective protein 6, revealing the basis for their mutual antagonism underpinning cell polarity. During starvation, muscle strength ...
News Medical on MSN5d
Trametinib shows promise in treating severe hypertrophic cardiomyopathy in children
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase transition ...
The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results